However, complement deficiencies, the over-expression of membrane complement regulatory proteins (e.g. CD55, CD59, and CD46) and fluid phase inhibitors (e.g. CFH, CFHR5, and C4BP) in the tumor microenvironment often cause resistance and non-responsiveness to mAb treatment (64, 82–84). This evidence concerns the gene CD59 and neoplasm.